摘要
目的研究吉西他滨联合顺铂治疗中晚期食管癌的疗效。方法选择在我院就诊的中晚期食管癌患者作为研究对象,随机分为给予吉西他滨联合顺铂治疗的观察组和紫杉醇联合顺铂治疗的对照组,观察肿瘤缓解情况、不良反应例数、总体生活质量。结果观察组化疗缓解率为76.67%、KPS评分(85.12±8.96)分、QLQ-C30评分(88.13±9.56)分高于对照组,出现恶心呕吐3例、肝功能损害2例、肾功能损害2例,均低于对照组,差异均有统计学意义(P<0.05)。结论吉西他滨联合顺铂化疗能够改善化疗效果、减少不良反应,具有积极的治疗价值。
Objective To study the efficacy of gemcitabine combined with cisplatin in treating advanced esophageal cancer. Methods Patients with advanced esophageal carcinoma were collected and randomly divided into observation group given gemcitabine combined with cisplatin and control group given paclitaxel combined with cisplatin. Then tumor relief condition,cases of adverse reactions,overall life quality and immune function were observed. Results Chemotherapy remission rate 76.67%,KPS score（85.12 ± 8.96）, QLQ-C30 score（88.13 ±9.56）of observation group were higher than control group,3 cases of nausea and vomiting,2 cases of liver function,2 cases of renal damage were lower than control group（P 〈 0.05）. Conclusion Gemcitabine and cisplatin chemotherapy has therapeutic value for improving the effect of chemotherapy and reducing the adverse reactions.
出处
《中国医药科学》
2013年第8期61-62,共2页
China Medicine And Pharmacy
关键词
食管癌
化疗
顺铂
吉西他滨
Esophageal carcinoma
Chemotherapy
Gemcitabine
Cisplatin
